This HTML5 document contains 93 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/wikipedia/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/bindingdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/pubchem-compound/
n31http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/iuphar/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/guide-to-pharmacology/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/national-drug-code-directory/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00841/identifier/chebi/
n22http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00841
rdf:type
n3:Drug
n3:description
A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
n3:dosage
n4:271B4A80-363D-11E5-9242-09173F13E4C5 n4:271B4A81-363D-11E5-9242-09173F13E4C5 n4:271B4A82-363D-11E5-9242-09173F13E4C5 n4:271B4A7F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 minutes
n3:indication
For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
n3:manufacturer
n6:271B4A7B-363D-11E5-9242-09173F13E4C5 n6:271B4A7C-363D-11E5-9242-09173F13E4C5 n6:271B4A79-363D-11E5-9242-09173F13E4C5 n6:271B4A7A-363D-11E5-9242-09173F13E4C5 n6:271B4A73-363D-11E5-9242-09173F13E4C5 n6:271B4A74-363D-11E5-9242-09173F13E4C5 n6:271B4A77-363D-11E5-9242-09173F13E4C5 n6:271B4A78-363D-11E5-9242-09173F13E4C5 n6:271B4A75-363D-11E5-9242-09173F13E4C5 n6:271B4A76-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00841 n31:DB00841
dcterms:title
Dobutamine
adms:identifier
n17:C06967 n18:D03879 n19:535 n20:535 n21:36811 n23:46505241 n24:55390-560-90 n25:PA449381 n26:50028971 n27:DB00841 n28:4670 n29:33786 n30:Dobutamine
n3:mechanismOfAction
Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.
n3:packager
n6:271B4A6F-363D-11E5-9242-09173F13E4C5 n6:271B4A70-363D-11E5-9242-09173F13E4C5 n6:271B4A6D-363D-11E5-9242-09173F13E4C5 n6:271B4A6E-363D-11E5-9242-09173F13E4C5 n6:271B4A6C-363D-11E5-9242-09173F13E4C5 n6:271B4A71-363D-11E5-9242-09173F13E4C5 n6:271B4A72-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
n3:synonym
rac-Dobutamine Dobutaminum Dobutamina Dobutamine 4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol Racemic-dobutamine Dobutamin DL-Dobutamine (+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol 3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
n10:hasAHFSCode
n11:12-12-08-08
n3:salt
n3:synthesisReference
R. R. Tuttle, J. Mills, DE 2317710 (1973). J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976).
foaf:page
n14:dobutamine.html n15:dobutamine.htm
n3:IUPAC-Name
n7:271B4A87-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4A8D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4A8C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4A89-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4A8A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4A8B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4A85-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4A86-363D-11E5-9242-09173F13E4C5 n7:271B4A83-363D-11E5-9242-09173F13E4C5 n7:271B4A9E-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4A84-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n22:C01CA07
n3:H-Bond-Acceptor-Count
n7:271B4A93-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4A94-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4A8E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4A8F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4A91-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4A90-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4A92-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
34368-04-2
n3:category
n3:containedIn
n5:271B4A7E-363D-11E5-9242-09173F13E4C5 n5:271B4A7D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4A99-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B4A9B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B4A9C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B4A9D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4A98-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4A97-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B4A9A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4A88-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B4A95-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4A96-363D-11E5-9242-09173F13E4C5